Guest article by Ravi Ramasamy
The orthopedic industry in the recent past has witnessed two major innovations as growth drivers. First the Robotics revolution – more of a Product innovation, (Driven by industry technology) and the second Ambulatory Surgery Centers (ASCs) - a Process innovation (Driven by external market dynamics). In the Pre COVID-19 period these two trends were the buzz words as every company wanting to be a player in these two areas invested heavily to grow their business. Some companies have seen a double-digit CAGR in the last five years with ASC.
However, post Covid-19, the dynamics are shifting more towards ASCs in the US markets, while robotics takes a hit temporarily but will regain after the vaccine for C-19 is released. The analyst predicts ASC doubling in growth from the 2019 growth of 15% in the coming months and years in the US market. In 2019, only 15% of recon procedures done in the ASC and this will increase to 30% - 35% in the second half of 2020 and continue to grow further in 2021 as long as clinically eligible patients (patient without any pre-clinical conditions) availability and the required infrastructure is in place.
ASC growth acce...
